O'Neill S K, Triggle C R, Bolger G T
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, AB, Canada.
Can J Physiol Pharmacol. 1994 Jul;72(7):738-45. doi: 10.1139/y94-105.
The binding of the dihydropyridine (+/-)-202-791 and its corresponding calcium channel activating and calcium channel antagonist enantiomers ((+)-S-202-791 and (-)-R-202-791, respectively) to dihydropyridine receptors on mouse brain membranes was studied through competition for [3H]nitrendipine binding and 3H-labelled (+/-)-BAY K8644 ((+/-)-[3H]BAY K8644). Direct binding studies with (+/-)-[3H]BAY K8644 and [3H]nitrendipine revealed high affinity binding to a homogeneous set of dihydropyridine calcium channel activator and antagonist receptors on mouse brain membranes, (+/-)-[3H]BAY K8644 binding to approximately one half as many receptors as did [3H]nitrendipine. Competition binding studies revealed a significant discrimination of both high and low affinity receptors for (-)-R-202-791 and a homogeneous set of receptors for (+)-S-202-791 regardless of whether (+/-)-[3H]BAY K8644 or [3H]nitrendipine was the competing radioligand. Molar ratios (1:1, 5:1, 10:1) of (+)-S-202-792 to (-)-R-202-791 inhibited [3H]nitrendipine binding with displacement binding isotherms substantially different from those predicted on the basis of the binding properties of the individual enantiomers. These data suggest that dihydropyridine calcium channel antagonists and activators bind to different allosterically linked receptors or domains of the dihydropyridine protein associated with the voltage-dependent calcium channels. Furthermore, these results support the concept of multiple binding sites for dihydropyridine ligands.
通过对[3H]尼群地平结合以及3H标记的(±)-BAY K8644((±)-[3H]BAY K8644)的竞争,研究了二氢吡啶(±)-202-791及其相应的钙通道激活剂和钙通道拮抗剂对映体(分别为(+)-S-202-791和(-)-R-202-791)与小鼠脑膜上二氢吡啶受体的结合。用(±)-[3H]BAY K8644和[3H]尼群地平进行的直接结合研究表明,它们与小鼠脑膜上一组同质的二氢吡啶钙通道激活剂和拮抗剂受体具有高亲和力结合,(±)-[3H]BAY K8644结合的受体数量约为[3H]尼群地平的一半。竞争结合研究表明,无论(±)-[3H]BAY K8644还是[RH]尼群地平作为竞争放射性配体,(-)-R-202-791对高亲和力和低亲和力受体都有显著区分,而(+)-S-202-791则是一组同质的受体。(+)-S-202-792与(-)-R-202-791的摩尔比(1:1、5:1、10:1)抑制[3H]尼群地平结合,其取代结合等温线与根据单个对映体的结合特性预测的等温线有很大不同。这些数据表明,二氢吡啶钙通道拮抗剂和激活剂与与电压依赖性钙通道相关的二氢吡啶蛋白的不同变构连接受体或结构域结合。此外,这些结果支持了二氢吡啶配体存在多个结合位点的概念。